Using Actisorb®: Case studies
This document contains a series of case reports describing the use of ACTISORB® (Systagenix) in patients with a range of wound types. All patients were treated for a minimum of 2–4 weeks and the decision to continue with ACTISORB® was based on continual assessment. A formal assessment was performed weekly, although in some cases dressing changes were carried out more frequently.
All patients were assessed for:
- clinical signs of infection/critical colonisation with or without odour
- signs of improvement, including odour reduction, granulation extent
- and reduction in wound size.
A pain assessment was carried out at the initial examination using a visual analogue scale (VAS) where 1 = no pain and 10 = unbearable pain.
Photographs were taken weekly in the majority of cases to document wound progression. Relevant additional wound treatments, eg compression therapy, antibiotic therapy, analgesia, etc, were reported. The clinicians undertaking the study were also asked to rate the dressing (from highly satisfied to dissatisfied) and to comment on the ease of use.
In addition, clinicians were offered the opportunity to check the protease activity in the wound using a WOUNDCHEK™ Protease Status test (Systagenix).
The weekly assessment outcomes are cited for each case where:
↓ = reduction
↑ = increase
- = no change.
This document has been jointly developed by Wounds International and Systagenix with financial support from Systagenix.